DR. REENA BHARTI

DR. ASHUTOSH MAHARANA

Abstract

This article reviews the available anti-VEGF drugs, their role in management of DME and an evidence-based guideline to select the appropriate anti-VEGF for a given patient. It has been well established that Chronic retinal microvascular damage occurring in diabetic retinopathy contributes to the production of VEGF which can lead to development of diabetic macular oedema (DME) as a result of the ongoing inflammatory process. The aim of this review was to compare the effects of available Anti-VEGFs in preserving and improving vision, and treatment acceptability (safety, compliance with therapy and quality of life) of for the treatment of DME and synthesizing an algorithm for selecting the suitable Anti-VEGF for a given patient. We devise a flowchart to propose the use of anti-VEGF therapy as the first line of treatment for optimum cost benefit ratio and clinical outcomes.